- Home
- SVII vs NSPR Comparison
SVII vs NSPR Comparison
Compare SVII & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- NSPR
- Stock Information
- Founded
- SVII 2021
- NSPR 2005
- Country
- SVII United States
- NSPR United States
- Employees
- SVII N/A
- NSPR N/A
- Industry
- SVII Blank Checks
- NSPR Medical/Dental Instruments
- Sector
- SVII Finance
- NSPR Health Care
- Exchange
- SVII Nasdaq
- NSPR Nasdaq
- Market Cap
- SVII 119.4M
- NSPR 101.8M
- IPO Year
- SVII 2022
- NSPR N/A
- Fundamental
- Price
- SVII $12.19
- NSPR $2.38
- Analyst Decision
- SVII
- NSPR Strong Buy
- Analyst Count
- SVII 0
- NSPR 2
- Target Price
- SVII N/A
- NSPR $4.50
- AVG Volume (30 Days)
- SVII 23.5K
- NSPR 78.3K
- Earning Date
- SVII 01-01-0001
- NSPR 11-11-2025
- Dividend Yield
- SVII N/A
- NSPR N/A
- EPS Growth
- SVII N/A
- NSPR N/A
- EPS
- SVII 0.17
- NSPR N/A
- Revenue
- SVII N/A
- NSPR $7,066,000.00
- Revenue This Year
- SVII N/A
- NSPR $7.48
- Revenue Next Year
- SVII N/A
- NSPR $104.39
- P/E Ratio
- SVII $72.64
- NSPR N/A
- Revenue Growth
- SVII N/A
- NSPR 7.60
- 52 Week Low
- SVII $11.20
- NSPR $1.99
- 52 Week High
- SVII $12.74
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- SVII 59.54
- NSPR 44.77
- Support Level
- SVII $12.04
- NSPR $2.35
- Resistance Level
- SVII $12.35
- NSPR $2.45
- Average True Range (ATR)
- SVII 0.10
- NSPR 0.08
- MACD
- SVII 0.00
- NSPR -0.00
- Stochastic Oscillator
- SVII 63.64
- NSPR 23.53
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.